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Abstract
Background: The liver is a common site of metastases, followed by the bone and lung in breast cancer. The
symptoms of hepatic metastases are similar to intrahepatic cholangiocarcinoma (ICC). ICC is rare, with an overall
incidence rate of 0.95 cases per 100,000 adults. The incidence of ICC for patients with breast cancer is very
uncommon. Breast cancer patient with ICC is easily misdiagnosed as hepatic metastases.
Case presentation: We report a breast cancer patient postoperatively who was hospitalized because of having
continuous irregular fever for 1 month. Antibiotics were given for 1 week without any significant effect. Her
admission bloods revealed elevated levels of carcino-embryonic antigen. Magnetic resonance imaging diagnosis
showed multiple liver metastases. We believed that the woman had hepatic metastases until biopsy guided by
computed tomography. The liver biopsy pathology analysis considered the possibility of primary intrahepatic
cholangiocarcinoma.
Conclusions: Breast cancer patient with space-occupying lesions in the liver is easily considered to be progressed
hepatic metastases. Image-guided biopsy is the best diagnostic method for breast cancer with liver mass to avoid
misdiagnosis and classify the molecular subtypes to make appropriate treatment.
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Background
Intrahepatic cholangiocarcinoma (ICC) is a rare tumor,
accounting for 3 % of all gastrointestinal malignancies
worldwide [1–4]. With similar signs and symptoms to
metastatic hepatic carcinoma including right abdominal
pain, low-grade fever, nausea, anorexia, weight loss, and
jaundice, ICC lacks typical clinical manifestations and is
hard to differentiate from liver metastases using imaging
modalities and tumor markers. For breast cancer, the
liver metastatic is common [5, 6]. Approximately, in
10 % of the cases, distant metastases are already present
at the time of diagnosis, and it is considered that more
than 50 % of the patients with advanced breast cancer
will develop hepatic metastasis at some point [7–9]. The
main treatment to breast cancer with hepatic metastasis
is systemic chemotherapy; however, curative resections
are the only currently well-established option for ICC.
Pathologic diagnosis is important to breast cancer pa-
tient with space-occupying lesions of the liver in order
to avoid misdiagnosis and mistherapy. In the case
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presented here, we report a breast cancer patient post-
operatively diagnosed with ICC other than hepatic
metastases.
Case presentation
A 48-year-old woman with “left breast cancer” was hos-
pitalized in Shandong Cancer Hospital & Institute. This
patient underwent modified radical mastectomy on July
18, 2014. Pathology diagnosis (Fig. 1): invasive ductal
carcinoma, maximum diameter of the mass is 1.3 cm.
Axillary lymph nodes involved level I 3/20, level II 0/20,
and level III 0/1. The pathological staging was T1N1M0,
stage IIA, which predicts the locally advanced disease.
Immunohistochemistry results are the following: ER (−),
PR (−), CerbB-2 positive (3+), and Ki-67+ (20 %). The
patient refused targeted trastuzumab therapy because of
personal economic situation. Chemotherapy regimen in-
cluding AC (pirarubicin, 80 mg, d1; cyclophosphamide,
0.8 g, d1) sequential TP (docetaxel, 120 mg d1; cis-
platinum, 60 mg d1, d2) was implemented after oper-
ation. Next, local radiotherapy was implemented on the
left side of the chest wall and the left clavicle lymph
drainage area, DT 50 Gy/25 times.
Fourteen months later, this patient was again hospital-
ized on Sep.19, 2015, because of having continuous
irregular fever for 1 month. Antibiotics were given for
1 week without any significant effect observed. We ex-
cluded the possibility of common infectious diseases.
Computed tomography (CT) revealed low-density foci in
the right liver lobe. The carcino-embryonic antigen
(CEA) was 7.29 ng/mL, while the standard value is less
than 3.4 ng/mL. We suspected the women had liver me-
tastasis after breast cancer surgery, and the magnetic
resonance imaging (MRI) abdomen diagnosis on Sep.20,
2015, was consistent with what we had suspected (Fig. 2).
Neither cerebral MRI nor whole body bone scan re-
vealed obvious abnormity or other distant metastases.
However, on Sep.23, 2015, pathology analysis through
row CT-guided liver biopsy demonstrated for poorly dif-
ferentiated adenocarcinoma. Furthermore, the photomi-
crographs (Fig. 3) including eosin staining (HE), CK7,
and CK19 accord with the characteristics of the low dif-
ferentiation of intrahepatic bile duct carcinoma (ICC),
which is the primary intrahepatic lesions.
Discussion
Breast cancer, the most common malignant cancer in
women worldwide, is a main cause of cancer death in fe-
males and the second in the general population just after
lung cancer. Liver metastases have a 5-year survival rate
Fig. 1 Photomicrographs of invasive breast carcinoma. a Light microscopy sections with hematoxylin and eosin staining demonstrating markedly
atypical endothelial cells (HE, ×200). b The chief cells showed positive staining to CD10 (IHC, ×100)
Fig. 2 Liver magnetic resonance image (MRI) after the patient have continued irregular fever for 1 month
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of 0 to 12 %, which is the poorest prognosis of all types
of breast cancer metastases [10]. Metastases seed the
liver via systemic circulation with a microscopic dissem-
ination and may be present in multiple sites [11–13].
Considering this patient with lymph node metastasis and
positive CerbB-2 expression, she was suspected of get-
ting liver metastases first, and the MRI imaging ap-
proved this hypothesis. Symptoms such as abdominal
fullness, back pain, fatigue, nausea, anorexia, low-grade
fever, and weight loss usually occur during the progres-
sion of liver metastasis. In this case, we hypothesize that
the fever of the woman may result from tumor tissue ne-
crosis, infection, and tumor metabolites. The vast major-
ity of patients with liver metastasis from breast cancer
also have metastasis in other parts of their bodies. Thus,
systemic treatment served as a better choice. Due to the
limitation of operation range, surgical practice in pa-
tients with liver metastasis from breast cancer is still
under debate. The majority of clinicians do not support
surgery with the role of surgery being strictly limited for
palliation of metastatic complications or locoregional re-
lapse, while others supported this method for its cost-
effectiveness with superior 5-year survival for selected
patients with isolated liver metastases and in those with
well-controlled minimal extrahepatic disease [14, 15].
ICC is one of the primary malignant liver tumors with
a prevalence of 5–20 % in hepatic carcinoma cases [16].
Although patients with ICC exhibited hepatic region
pain, weight loss, or few of irregular fever, a considerable
number of patients are asymptomatic [17, 18]. The
patient in our report had fever as the first symptom is
easily misdiagnosed. The nonspecific tumor markers
CEA can be found elevated both in ICC and in liver me-
tastasis. It is not helpful for us to do a differential diag-
nosis with this woman who only had CEA elevated [17].
Imaging features of ICC are space-occupying lesions in
the liver [19], which we are easily confused with liver
metastases. Due to the challenges in their detection and
treatment, ICC is usually already progressed invasively
and transfers to the lymphatic system during its early
stage [20, 21]. Though the resectability and curability re-
main low compared to other hepatobiliary tumors, surgi-
cal resection is the preferred treatment for the ICC [22].
This breast cancer patient 1 year after surgery has con-
tinuous irregular fever for 1 month, and 1-week intraven-
ous antibiotics were of no use. With the MRI imaging
findings and elevated levels of CEA, as well as the unstan-
dardized treatment of HER2 target, we easily believed that
this breast cancer patient had hepatic metastases. But the
liver biopsy pathology analysis by CT-guided biopsy led us
to consider the possibility of primary ICC.
Conclusions
This breast cancer patient postoperatively was diagnosed
to hepatic metastases with the clinical symptoms and
imaging diagnosis until the biopsy results were reported
to primary ICC. For breast cancer patients with liver
space-occupying lesions, we should not treat them im-
prudently to the liver metastasis of breast cancer. In-
stead, we should make careful judgment bases on the
biopsy and pathology diagnosis, providing the basis for
subsequent treatment. Imaging-guided biopsy should be
chosen to breast cancer patient with space-occupying le-
sions of the liver in order to avoid misdiagnosis and clas-
sify the molecular subtypes to make appropriate
treatment.
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